By partnering with patients to design and develop new solutions, we can co-create methods for them to achieve their health goals.
To pave the path for new innovations in research and lifecycle of medicine development, we intend to improve the patient experience by prioritizing patient preferences and values and creating synergies across interventions which involve the voice of the patient.
We partner WITH patients.
Medicines are developed to improve the lives of patients. By involving patients throughout the development process, drug trials can be designed to better reflect patient needs and accommodate the challenges they face. This can lead to improved participation rates in trials, help development of innovative medicines, allow more rapid access to new therapies, and improve health outcomes for patients.
Serving patients in the best way possible requires a deep understanding of their medical condition, which can be can be gained only through direct, sustained and constructive interactions with patients. Health stakeholders have converged on the idea that broadening patient engagement is key to improving drug development.
While stakeholders have started to develop guidelines and methodologies to improving patient engagement in medicines development, this is still in its infancy, and existing approaches are fragmented. An efficient, measurable and reliable framework that involves patients as partners has yet to be developed, validated and applied.
The Patient Focused Medicines Development (PFMD) group, established in 2015, is an independent multinational coalition, managed in collaboration with The Synergist. Its goal is to bring together initiatives and best practices that integrate the voice of the patient throughout the lifecycle of medicines development, thereby speeding up the creation and implementation of an effective, globally standardized framework.
PFMD seeks to have a balanced representation of stakeholders to ensure transparency, inclusiveness, and credibility. Stakeholders include patients and patient organizations across diverse areas of health and industry. We also intend to invite regulators, payers and other professional organizations to the global group to ensure diversity of perspectives.
Remove the barriers to effective patient engagement
Find out how in our new paper – “Culture and process change as a priority for patient engagement in medicines development” – published in the peer-reviewed journal Therapeutic Innovation & Regulatory Science (TIRS)
Our approach to synergizing
Create standards throughout the lifecycle of medicine development that unify diverse stakeholders towards a common goal of improved health.Harmonization
EngagementAlign lifecycle of medicine development with patient needs and priorities across a global framework.
Foster innovation by identifying gaps, showcasing good practices and identifying new opportunities.Innovation
ExchangeFacilitate sharing of information across healthcare through a learning exchange that promotes patient engagement.
PFMD Governance Model
Inclusive & Expert Advice
- Advisory Committee
Funding and/or participating in kind
- PFMD Member Organisations
- Patient representatives
Pharma companies (committed to adopt the new framework)
Agile & Driven Operations
- Management Group
Data Framework & Related Services
Reporting & transparency